Aldevron and Integrated DNA Technologies – both part of the Danaher Corporation – have achieved a medical milestone with the successful manufacture of the world’s first personalized CRISPR gene-editing drug product to treat an infant suffering from a rare and life-threatening genetic condition known as urea cycle disorder (UCD).

Steven Davis, Co-Founder and CEO of Bio::Neos, Inc. —a BioVentures Center tenant—received the Youth Engagement Award.

SunHydrogen has contracted The Process Group, LLC (TPG Engineers) for front-end engineering design of a >25-square-meter proof-of-concept hydrogen production pilot plant.

S5G Therapeutics, a startup comprised of experts in clinical and translational medicine, biomedical research, pharmaceutical sciences, and business development in the ocular therapeutics space, was awarded first place and $50,000 in the Graduate/Faculty/Staff/Incubator Startup division of Innovation Challenge.

Perspective Therapeutics has announced the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α).

Strategic partnership between IDT and Elegen marks launch of early access program offering rapid, long, clonal gene synthesis and high-complexity genes up to 15 kb

Dr. Mark Greiner and his research team, based at the Iowa Lions Eye Bank within the BioVentures Center, are using a five-year, $2.85 million grant from the National Eye Institute to develop a topical drug therapy designed to prevent vision loss caused by Fuchs endothelial corneal dystrophy.

While the world experiences volatility, our mission remains unchanged: to produce renewable hydrogen for the world at an economical price.

Perspective Therapeutics has announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET that are being presented as a poster presentation at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) taking place January 23-25, 2025 in San Francisco, CA.